"As lung cancer screening initiatives increase and we find more suspicious lung nodules, it is especially critical to provide minimally invasive diagnostic options earlier so patients can receive treatment sooner and have better chances of long-term survival," said Sandeep Khandhar, MD, a CVTSA thoracic, surgical director of thoracic oncology at Inova in Falls Church, Virginia and co-National Lead Investigator of the NAVIGATE study. "We are at a crucial time where diagnostic and surgical technologies have advanced to a level where I believe there could be a significant shift in patient outcomes and many patients can go on to lead long, active and healthy lives after a lung cancer diagnosis, which was almost unheard of even 10 years ago."
"Medtronic is committed to providing innovative diagnostic and therapeutic solutions for lung disease that have the potential to transform care and improve outcomes for patients worldwide," said Michael Tarnoff, MD, vice president and chief medical officer, Minimally Invasive Therapies Group at Medtronic. "We hope the NAVIGATE study will help confirm the impact of ENB procedures that we have seen in over 50,000 cases performed at more than 600 hospitals commercially and as part of prior clinical trials. Given the results seen to date, we are confident that this approach has the potential to become a recommended global standard of care to aid in diagnosis of peripheral lung lesions."
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
According to the American Lung Association, lung cancer is the leading cause of cancer-related deaths in the United States3. In its early stages, lung cancer presents few, if any, symptoms. As a result, diagnosis for the vast majority of lung cancer patients happens in the late stages, causing long-term survival rates to drastically decline. When diagnosed early, an estimated 85 percent of lung cancer cases appear at a more curable stage4. Early detection and immediate treatment dramatically increases the typical long-term survival rate from 15 percent at five years3 to 88 percent at 10 years4.
The superDimension system has received FDA 510(k) clearance in the United States, CE Mark in Europe and it has also been approved for use in numerous international markets.
Additional information about the NAVIGATE study and sites enrolling can be found at https://clinicaltrials.gov/ct2/show/NCT02410837.
Multimedia Release
A multimedia version of this release, with video and links to graphics can be found at: http://bit.ly/1Ywv08W.
